225 related articles for article (PubMed ID: 19967774)
1. Erwinia asparaginase: coming closer to an understanding of its use in pediatric acute lymphoblastic leukemia?
Maloney KW
Pediatr Blood Cancer; 2010 Feb; 54(2):189-90. PubMed ID: 19967774
[No Abstract] [Full Text] [Related]
2. Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Salzer W; Seibel N; Smith M
Expert Opin Biol Ther; 2012 Oct; 12(10):1407-14. PubMed ID: 22946493
[TBL] [Abstract][Full Text] [Related]
3. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
5. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
7. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic pseudocyst complicating treatment of acute lymphoblastic leukemia.
Tomar S; Bakhshi S; Kabra SK; Arya LS
Indian Pediatr; 2003 Jul; 40(7):670-2. PubMed ID: 12881625
[No Abstract] [Full Text] [Related]
9. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
11. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
12. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
[TBL] [Abstract][Full Text] [Related]
13. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
[TBL] [Abstract][Full Text] [Related]
14. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
16. Transient hyperthyroidism following L-asparaginase therapy for acute lymphoblastic leukemia.
Fadilah SA; Faridah I; Cheong SK
Med J Malaysia; 2000 Dec; 55(4):513-5. PubMed ID: 11221167
[TBL] [Abstract][Full Text] [Related]
17. Thyroid function is not affected by second exposure to erwinia asparaginase for childhood acute lymphoblastic leukemia.
Bossi G; Larizza D; Conter V
Haematologica; 1997; 82(4):507-8. PubMed ID: 9299875
[No Abstract] [Full Text] [Related]
18. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
19. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic bone marrow transplantation after L-asparaginase-induced pancreatitis in a patient with acute lymphoblastic leukemia.
Yamada Y; Ito K; Watanabe Y; Nosaka K; Horikawa K; Hidaka M; Kawano F; Sasaki Y; Mitsuya H; Asou N
Leuk Res; 2008 Dec; 32(12):1944-6. PubMed ID: 18502503
[No Abstract] [Full Text] [Related]
[Next] [New Search]
